Therefore, COPD-linked inflammation likely affects the clinical response to PD-1 blockade and NSCLC patients with a coexisting COPD may qualify for the treatment with immune checkpoint inhibitor20,23,24. The gene discussed is PDCD1; the disease is chronic obstructive pulmonary disease.